Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20203573 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2MEN1KMT2ATP53LMNA | |
| SCHEMBL20037735 | 0.88 | TP53 (0.37) | SMN1; SMN2MEN1KMT2ATP53LMNA | |
| SCHEMBL20037602 | 0.87 | HASPIN (0.37) | SMN1; SMN2TP53LMNAPOLBALDH1A1 | |
| SCHEMBL20203400 | 0.86 | TP53 (0.44) | TP53LMNAPOLBMAPTNTRK1 | |
| SCHEMBL20203496 | 0.86 | TP53 (0.44) | TP53LMNAPOLBMAPTNTRK1 | |
| SCHEMBL31164075 | 0.85 | NPC1 (0.36) | SMN1; SMN2MEN1KMT2ATP53LMNA | |
| SCHEMBL20037653 | 0.85 | PKM (0.39) | SMN1; SMN2TP53LMNAPOLBALDH1A1 | |
| SCHEMBL20207274 | 0.85 | PKM (0.39) | SMN1; SMN2TP53LMNAPOLBALDH1A1 | |
| SCHEMBL20203576 | 0.83 | LMNA (0.39) | SMN1; SMN2MEN1KMT2ATP53LMNA | |
| SCHEMBL20203513 | 0.81 | KMT2A (0.42) | MEN1KMT2ATP53LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261182-B2 | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof | TEIJIN PHARMA LIMITED (JP) | 2022-03-01 | — | — | US | disclosed |
| EP-3546456-B1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3546456-B1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LTD (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20210276997-A1 | CRYSTAL OF PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | TEIJIN PHARMA LIMITED (JP) | 2021-09-09 | — | — | US | disclosed |
| EP-3546456-A1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018097295-A1 | CRYSTAL OF PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261182-B2 | Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof | CDK6, CDK4, CDKL4 | SMN1; SMN2 3386/4885MEN1 3168/4885KMT2A 724/4885 |
| US-20210276997-A1 | CRYSTAL OF PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF | CDK6, CDK4, CDKL4 | SMN1; SMN2 3386/4885MEN1 3168/4885KMT2A 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.